Neuracle Science Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2015-10-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.neuracles.com
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Phase 1
Recruiting
- Conditions
- Seneorineural DeafnessSudden Sensorineural Hearing Loss
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Neuracle Science Co., LTD.
- Target Recruit Count
- 118
- Registration Number
- NCT06249919
- Locations
- 🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷SCH University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of
A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
Phase 1
Completed
- Conditions
- Neurodegenerative Diseases
- Interventions
- Drug: NS101 IV infusion
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Neuracle Science Co., LTD.
- Target Recruit Count
- 64
- Registration Number
- NCT05143463
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
© Copyright 2025. All Rights Reserved by MedPath